ClinicalTrials.gg
CompletedNCT01681121Updated May 28, 2021Results posted

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

A Phase 2 interventional study of ADX-N05 and Placebo in Narcolepsy, sponsored by Jazz Pharmaceuticals. Completed at 28 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-05-28.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Narcolepsy by Jazz Pharmaceuticals — 1 open to participants now, 1 under way, 1 of them phase 3. Narcolepsy · Jazz Pharmaceuticals.

Enrollment
10th of 15
93 · median 120
Started
2012
the only one that year
Phase 2
3 of 18
none open now
Registered
5th of 18
by date

Among the 18 studies in Narcolepsy by Jazz Pharmaceuticals, this one is the 10th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2012, is one of 3 in phase 2, and was the 5th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

1 of the 18 studies in Narcolepsy by Jazz Pharmaceuticals is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Narcolepsy by Jazz Pharmaceuticals, or all of them as a file.
02

Study summary

This is a study to evaluate the safety and effectiveness of ADX-N05 compared to placebo in the treatment of excessive daytime sleepiness in adults with narcolepsy.

03

Conditions studied

  • Narcolepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of narcolepsy
  • Good general health
  • Willing and able to comply with the study design and schedule and other requirements

Exclusion criteria

Exclusion Criteria:

  • If female, pregnant or lactating
  • Customary bedtime later than midnight
  • History of significant medical condition, behavioral, or psychiatric disorder (including suicidal ideation), or surgical history
  • Any other medical, behavioral or psychiatric disorder other than narcolepsy that is associated with excessive sleepiness
  • History of significant cardiovascular disease
  • > 34
  • Excessive caffeine use - > 600 mg/day of caffeine or > 6 cups of coffee/day
  • History of alcohol or drug abuse within the past 2 years
  • Nicotine dependence that has an effect on sleep
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    ADX-N05

    ADX-N05 to be taken once a day for 12 weeks

    Drug: ADX-N05

  • Placebo comparator
    Placebo

    Placebo to match ADX-N05 to be taken once a day for 12 weeks

    Drug: Placebo

Interventions

  • 150 mg once a day for 4 weeks followed by 300 mg once a day for 8 weeks

  • DrugPlacebo

    One capsule placebo to match ADX-N05 to be taken for 4 weeks followed by 2 capsules placebo to match ADX-N05 to be taken for 8 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) for ADX-N05 300 mg vs. Placebo at Last Assessment.

    The MWT is a validated objective measure of the ability to stay awake for a defined period of time. The primary analysis was a comparison of treatments vs. control groups on change from Baseline to last available post-Baseline assessment (Week 12/Last Assessment) in the average sleep latency time (in minutes) averaged across the first four trials of the MWT using a two-sample t-test.

    Time frame: Baseline up to Week 12/Last Assessment post-dose.

  2. Number of Participants With Improved Clinical Global Impression of Change (CGI-C) Scores for ADX-N05 vs. Placebo at Last Assessment

    The CGI-C scale rated the change in the participant's condition as compared to the Baseline visit on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The proportion of subjects experiencing at least minimal improvement on the CGI-C was calculated and summarized for each of the treatment groups at Week 4 and the last available post-Baseline assessment (Week 12/Last Assessment). The CGI-C scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Improvement was defined as a CGI-rating of 1, 2, or 3.

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) (Average of the First Four Trials) Following Four Weeks of Treatment With ADX-N05 150 mg vs. Placebo

    The MWT is a validated objective measure of the ability to stay awake for a defined period of time. The MWT consisted of five 40-minute trials separated by 2 hour intervals. This secondary analysis repeated the primary analysis for effects at the end of Week 4.

    Time frame: Baseline up to Week 4 post-dose.

  2. Change From Baseline in Sleep Latency Time (in Minutes) as Determined From Each of the 5 Individual MWT Trials for ADX-N05 vs. Placebo at Week 4

    The MWT is a validated objective measure of the ability to stay awake for a defined period of time. The MWT consisted of five 40-minute trials separated by 2 hour intervals. This secondary analysis repeated the primary analysis for effects for the five MWT trials analyzed separately at Week 4.

    Time frame: Baseline up to Week 4 post-dose.

  3. Change From Baseline in Sleep Latency Time (in Minutes) as Determined From Each of the 5 Individual MWT Trials for ADX-N05 vs. Placebo at Last Assessment

    The MWT is a validated objective measure of the ability to stay awake for a defined period of time. The MWT consisted of five 40-minute trials separated by 2 hour intervals. This secondary analysis repeated the primary analysis for effects for the five MWT trials analyzed separately at the last available post-Baseline assessment (Week 12/Last Assessment).

    Time frame: Baseline up to Week 12/Last Assessment post-dose.

  4. Change From Baseline in Epworth Sleepiness Scale (ESS) Scores for ADX-N05 vs. Placebo at Week 4

    The ESS is a questionnaire intended to measure daytime sleepiness. In this test, participants answer questions with regard to the level of sleepiness they experienced over approximately the 7 days prior to the assessment while performing eight common, non-stimulating activities. The ESS total score range is 1 to 24. Each activity is rated on a 4-point scale ranging from a minimum of "would never doze" to a maximum of "a high chance of dozing." Thus, the ESS scale range is as follows: 0=would never doze, 1=slight chance of dozing, 2=moderate chance of dozing, 3=high chance of dozing; 0 indicates a better outcome, and 3 indicates a worse outcome. A negative mean change value indicates a decrease in score from baseline and an improvement in daytime sleepiness.

    Time frame: Baseline up to Week 4 post-dose.

  5. Change From Baseline in ESS Scores for ADX-N05 vs. Placebo at Last Assessment

    The ESS is a questionnaire intended to measure daytime sleepiness. In this test, participants answer questions with regard to the level of sleepiness they experienced over approximately the 7 days prior to the assessment while performing eight common, non-stimulating activities. The ESS total score range is 1 to 24. Each activity is rated on a 4-point scale ranging from a minimum of "would never doze" to a maximum of "a high chance of dozing." Thus, the ESS scale range is as follows: 0=would never doze, 1=slight chance of dozing, 2=moderate chance of dozing, 3=high chance of dozing; 0 indicates a better outcome, and 3 indicates a worse outcome. A negative mean change value indicates a decrease in score from baseline and an improvement in daytime sleepiness.

    Time frame: Baseline up to Week 12/Last Assessment post-dose.

  6. Number of Participants With Improved Clinical Global Impression of Change (CGI-C) Scores for ADX-N05 vs. Placebo at Week 4

    The CGI-C scale rated the change in the participant's condition as compared to the Baseline visit on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The proportion of subjects experiencing at least minimal improvement on the CGI-C was calculated and summarized for each of the treatment groups at Week 4 and the last available post-Baseline assessment (Week 12/Last Assessment). The CGI-C scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Improvement was defined as a CGI-rating of 1, 2, or 3.

    Time frame: Week 4

  7. Number of Participants With Improved Patient Global Impression Change (PGI-C) Scores for ADX-N05 vs. Placebo at Week 4

    The Patient Global Impression - Change (PGI-C) scale was completed by the subject at the Weeks 1, 2, 4, 6, 8, and 12 visits. The CGI-C scale rated the change in the participant's condition as compared to the Baseline visit on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The proportion of subjects experiencing at least minimal improvement on the CGI-C was calculated and summarized for each of the treatment groups at Week 4 and the last available post-Baseline assessment (Week 12/Last Assessment). The CGI-C scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Improvement was defined as a CGI-rating of 1, 2, or 3.

    Time frame: Week 4

  8. Number of Participants With Improved PGI-C Scores for ADX-N05 vs. Placebo at Last Assessment

    The Patient Global Impression - Change (PGI-C) scale was completed by the subject at the Weeks 1, 2, 4, 6, 8, and 12 visits. The CGI-C scale rated the change in the participant's condition as compared to the Baseline visit on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The proportion of subjects experiencing at least minimal improvement on the CGI-C was calculated and summarized for each of the treatment groups at Week 4 and the last available post-Baseline assessment (Week 12/Last Assessment). The CGI-C scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Improvement was defined as a CGI-rating of 1, 2, or 3.

    Time frame: Week 12/Last Assessment

07

Results

Posted Sep 11, 2014

Participant flow

Participant flow — Overall Study
MilestoneADX-N05Placebo
Started4449
Completed3638
Not completed811

Outcome measures

PrimaryChange From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) for ADX-N05 300 mg vs. Placebo at Last Assessment.

The MWT is a validated objective measure of the ability to stay awake for a defined period of time. The primary analysis was a comparison of treatments vs. control groups on change from Baseline to last available post-Baseline assessment (Week 12/Last Assessment) in the average sleep latency time (in minutes) averaged across the first four trials of the MWT using a two-sample t-test.

Time frame:
Baseline up to Week 12/Last Assessment post-dose.
Reported as:
Mean · minutes
Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) for ADX-N05 300 mg vs. Placebo at Last Assessment.
minutesADX-N05Placebo
Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) for ADX-N05 300 mg vs. Placebo at Last Assessment.12.8 ± 10.282.1 ± 7.88
PrimaryNumber of Participants With Improved Clinical Global Impression of Change (CGI-C) Scores for ADX-N05 vs. Placebo at Last Assessment

The CGI-C scale rated the change in the participant's condition as compared to the Baseline visit on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The proportion of subjects experiencing at least minimal improvement on the CGI-C was calculated and summarized for each of the treatment groups at Week 4 and the last available post-Baseline assessment (Week 12/Last Assessment). The CGI-C scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Improvement was defined as a CGI-rating of 1, 2, or 3.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants With Improved Clinical Global Impression of Change (CGI-C) Scores for ADX-N05 vs. Placebo at Last Assessment
ParticipantsADX-N05Placebo
Number of Participants With Improved Clinical Global Impression of Change (CGI-C) Scores for ADX-N05 vs. Placebo at Last Assessment3718
SecondaryChange From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) (Average of the First Four Trials) Following Four Weeks of Treatment With ADX-N05 150 mg vs. Placebo

The MWT is a validated objective measure of the ability to stay awake for a defined period of time. The MWT consisted of five 40-minute trials separated by 2 hour intervals. This secondary analysis repeated the primary analysis for effects at the end of Week 4.

Time frame:
Baseline up to Week 4 post-dose.
Reported as:
Mean · minutes
Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) (Average of the First Four Trials) Following Four Weeks of Treatment With ADX-N05 150 mg vs. Placebo
minutesADX-N05Placebo
Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) (Average of the First Four Trials) Following Four Weeks of Treatment With ADX-N05 150 mg vs. Placebo9.5 ± 8.381.4 ± 7.59
SecondaryChange From Baseline in Sleep Latency Time (in Minutes) as Determined From Each of the 5 Individual MWT Trials for ADX-N05 vs. Placebo at Week 4

The MWT is a validated objective measure of the ability to stay awake for a defined period of time. The MWT consisted of five 40-minute trials separated by 2 hour intervals. This secondary analysis repeated the primary analysis for effects for the five MWT trials analyzed separately at Week 4.

Time frame:
Baseline up to Week 4 post-dose.
Reported as:
Mean · minutes
Change From Baseline in Sleep Latency Time (in Minutes) as Determined From Each of the 5 Individual MWT Trials for ADX-N05 vs. Placebo at Week 4
minutesADX-N05Placebo
Trial 111.7 ± 12.501.6 ± 9.86
Trial 29.7 ± 12.511.0 ± 9.01
Trial 39.9 ± 11.441.3 ± 9.86
Trial 46.8 ± 10.561.8 ± 7.64
Trial 55.4 ± 9.10-4.0 ± 12.28
SecondaryChange From Baseline in Sleep Latency Time (in Minutes) as Determined From Each of the 5 Individual MWT Trials for ADX-N05 vs. Placebo at Last Assessment

The MWT is a validated objective measure of the ability to stay awake for a defined period of time. The MWT consisted of five 40-minute trials separated by 2 hour intervals. This secondary analysis repeated the primary analysis for effects for the five MWT trials analyzed separately at the last available post-Baseline assessment (Week 12/Last Assessment).

Time frame:
Baseline up to Week 12/Last Assessment post-dose.
Reported as:
Mean · minutes
Change From Baseline in Sleep Latency Time (in Minutes) as Determined From Each of the 5 Individual MWT Trials for ADX-N05 vs. Placebo at Last Assessment
minutesADX-N05Placebo
Trial 115.5 ± 13.842.6 ± 10.65
Trial 213.4 ± 15.312.7 ± 10.97
Trial 311.4 ± 12.622.0 ± 10.83
Trial 410.8 ± 13.851.0 ± 6.92
Trial 58.2 ± 12.73-1.6 ± 13.12
SecondaryChange From Baseline in Epworth Sleepiness Scale (ESS) Scores for ADX-N05 vs. Placebo at Week 4

The ESS is a questionnaire intended to measure daytime sleepiness. In this test, participants answer questions with regard to the level of sleepiness they experienced over approximately the 7 days prior to the assessment while performing eight common, non-stimulating activities. The ESS total score range is 1 to 24. Each activity is rated on a 4-point scale ranging from a minimum of "would never doze" to a maximum of "a high chance of dozing." Thus, the ESS scale range is as follows: 0=would never doze, 1=slight chance of dozing, 2=moderate chance of dozing, 3=high chance of dozing; 0 indicates a better outcome, and 3 indicates a worse outcome. A negative mean change value indicates a decrease in score from baseline and an improvement in daytime sleepiness.

Time frame:
Baseline up to Week 4 post-dose.
Reported as:
Mean · score on a scale
Change From Baseline in Epworth Sleepiness Scale (ESS) Scores for ADX-N05 vs. Placebo at Week 4
score on a scaleADX-N05Placebo
Change From Baseline in Epworth Sleepiness Scale (ESS) Scores for ADX-N05 vs. Placebo at Week 4-5.6 ± 5.28-2.4 ± 4.60
SecondaryChange From Baseline in ESS Scores for ADX-N05 vs. Placebo at Last Assessment

The ESS is a questionnaire intended to measure daytime sleepiness. In this test, participants answer questions with regard to the level of sleepiness they experienced over approximately the 7 days prior to the assessment while performing eight common, non-stimulating activities. The ESS total score range is 1 to 24. Each activity is rated on a 4-point scale ranging from a minimum of "would never doze" to a maximum of "a high chance of dozing." Thus, the ESS scale range is as follows: 0=would never doze, 1=slight chance of dozing, 2=moderate chance of dozing, 3=high chance of dozing; 0 indicates a better outcome, and 3 indicates a worse outcome. A negative mean change value indicates a decrease in score from baseline and an improvement in daytime sleepiness.

Time frame:
Baseline up to Week 12/Last Assessment post-dose.
Reported as:
Mean · score on a scale
Change From Baseline in ESS Scores for ADX-N05 vs. Placebo at Last Assessment
score on a scaleADX-N05Placebo
Change From Baseline in ESS Scores for ADX-N05 vs. Placebo at Last Assessment-8.5 ± 5.75-2.5 ± 5.13
SecondaryNumber of Participants With Improved Clinical Global Impression of Change (CGI-C) Scores for ADX-N05 vs. Placebo at Week 4

The CGI-C scale rated the change in the participant's condition as compared to the Baseline visit on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The proportion of subjects experiencing at least minimal improvement on the CGI-C was calculated and summarized for each of the treatment groups at Week 4 and the last available post-Baseline assessment (Week 12/Last Assessment). The CGI-C scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Improvement was defined as a CGI-rating of 1, 2, or 3.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Number of Participants With Improved Clinical Global Impression of Change (CGI-C) Scores for ADX-N05 vs. Placebo at Week 4
ParticipantsADX-N05Placebo
Number of Participants With Improved Clinical Global Impression of Change (CGI-C) Scores for ADX-N05 vs. Placebo at Week 43223
SecondaryNumber of Participants With Improved Patient Global Impression Change (PGI-C) Scores for ADX-N05 vs. Placebo at Week 4

The Patient Global Impression - Change (PGI-C) scale was completed by the subject at the Weeks 1, 2, 4, 6, 8, and 12 visits. The CGI-C scale rated the change in the participant's condition as compared to the Baseline visit on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The proportion of subjects experiencing at least minimal improvement on the CGI-C was calculated and summarized for each of the treatment groups at Week 4 and the last available post-Baseline assessment (Week 12/Last Assessment). The CGI-C scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Improvement was defined as a CGI-rating of 1, 2, or 3.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Number of Participants With Improved Patient Global Impression Change (PGI-C) Scores for ADX-N05 vs. Placebo at Week 4
ParticipantsADX-N05Placebo
Number of Participants With Improved Patient Global Impression Change (PGI-C) Scores for ADX-N05 vs. Placebo at Week 43320
SecondaryNumber of Participants With Improved PGI-C Scores for ADX-N05 vs. Placebo at Last Assessment

The Patient Global Impression - Change (PGI-C) scale was completed by the subject at the Weeks 1, 2, 4, 6, 8, and 12 visits. The CGI-C scale rated the change in the participant's condition as compared to the Baseline visit on a 7-point scale ranging from a minimum of "Very much improved" to a maximum of "Very much worse." The proportion of subjects experiencing at least minimal improvement on the CGI-C was calculated and summarized for each of the treatment groups at Week 4 and the last available post-Baseline assessment (Week 12/Last Assessment). The CGI-C scale consists of the following ratings: 1-Very Much improved, 2-Much improved, 3-Minimally improved, 4-No change, 5-Minimally worse, 6-Much worse, 7-Very much worse; a rating of 1 indicates a better outcome, and a rating of 7 indicates a worse outcome. Improvement was defined as a CGI-rating of 1, 2, or 3.

Time frame:
Week 12/Last Assessment
Reported as:
Count of participants · Participants
Number of Participants With Improved PGI-C Scores for ADX-N05 vs. Placebo at Last Assessment
ParticipantsADX-N05Placebo
Number of Participants With Improved PGI-C Scores for ADX-N05 vs. Placebo at Last Assessment4018

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ADX-N050/44 (0%)2/44 (4.5%)21/44 (47.7%)
Placebo0/49 (0%)0/49 (0%)12/49 (24.5%)
Most frequent serious events
Most frequent serious events
EventADX-N05Placebo
Conversion DisorderPsychiatric disorders1/440/49
Cholecystitis AcuteHepatobiliary disorders1/440/49
Most frequent other events
Showing 10 of 12
Most frequent other events
EventADX-N05Placebo
HeadacheNervous system disorders7/445/49
InsomniaNervous system disorders6/441/49
NauseaGastrointestinal disorders6/443/49
DiarrhoeaGastrointestinal disorders5/443/49
AnxietyPsychiatric disorders5/440/49
Upper Respirstory Tract InfectionInfections and infestations2/444/49
DizzinessNervous system disorders3/441/49
AgitationPsychiatric disorders3/440/49
BruxismPsychiatric disorders3/440/49
Initial InsomniaNervous system disorders2/442/49

Baseline characteristics

Age, Continuous
Age, Continuous(Years)ADX-N05PlaceboTotal
Mean41 ± 12.3336.7 ± 11.7138.7 ± 12.13
Sex: Female, Male
Sex: Female, Male(Participants)ADX-N05PlaceboTotal
Female303060
Male141933
08

Study locations

28 sites
  • Sleep Disorders Center of Alabama
    Birmingham, Alabama 35213, United States
  • Pulmonary Associates
    Phoenix, Arizona 85006, United States
  • Stanford Sleep Medicine Center
    Redwood City, California 94063, United States
  • Pacific Research Network
    San Diego, California 92103, United States
  • Sleep-Alertness Disorders Center
    Aurora, Colorado 80012, United States
  • PAB Clinical Research
    Brandon, Florida 33511, United States
  • Clinical Research Group of St. Petersburg
    Saint Petersburg, Florida 33707, United States
  • NeuroTrials Research, Inc.
    Atlanta, Georgia 30342, United States
  • Sleep Disorders Center of Georgia
    Atlanta, Georgia 30342, United States
  • SleepMed of Central Georgia
    Macon, Georgia 31201, United States
  • Chicago Research Center
    Chicago, Illinois 60634, United States
  • Community Research
    Crestview Hills, Kentucky 41017, United States
  • Kentucky Research Group
    Louisville, Kentucky 40217, United States
  • The Center for Sleep and Wake Disorders
    Chevy Chase, Maryland 20815, United States
  • Pulmonary and Critical Care Associates of Baltimore
    Towson, Maryland 21204, United States
  • Neurocare, Inc.
    Newton, Massachusetts 02459, United States
  • Minnesota Lung Center and Sleep Institute
    Edina, Minnesota 55435, United States
  • Washington University
    Saint Louis, Missouri 63108, United States
  • Rex Sleep Disorders Center
    Raleigh, North Carolina 27607, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Mercy St. Vincent Medical Center
    Toledo, Ohio 43623, United States
  • Center for Sleep Medicine
    Philadelphia, Pennsylvania 19118, United States
  • SleepMed of South Carolina
    Columbia, South Carolina 29201, United States
  • Future Search Trials of Neurology
    Austin, Texas 78731, United States
  • Sleep Medicine Associates of Texas
    Dallas, Texas 75231, United States
  • Todd J. Swick, MD, PA
    Houston, Texas 77063, United States
  • Metroplex Pulmonary and Sleep Center
    McKinney, Texas 75069, United States
  • Sleep Therapy and Research Center
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Ruoff C, Swick TJ, Doekel R, Emsellem HA, Feldman NT, Rosenberg R, Bream G, Khayrallah MA, Lu Y, Black J. Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study. Sleep. 2016 Jul 1;39(7):1379-87. doi: 10.5665/sleep.5968. PubMed 27166238 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2012
First posted
Sep 7, 2012
Start
Sep 2012
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Sep 11, 2014
Last update
May 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01681121
Responsible party
Sponsor
First posted
Sep 7, 2012
Start date
Sep 2012
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Sep 11, 2014
Last update
May 28, 2021

Study contacts

David Ward, MD
study director · Aerial BioPharma, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion